Clinical trials
Completed Recurrence trials in Canada
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
158 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2001 | 1 |
| 2003 | 5 |
| 2004 | 5 |
| 2005 | 8 |
| 2006 | 8 |
| 2007 | 13 |
| 2008 | 5 |
| 2009 | 12 |
| 2010 | 5 |
| 2011 | 12 |
| 2012 | 8 |
| 2013 | 5 |
| 2014 | 6 |
| 2015 | 9 |
| 2016 | 11 |
| 2017 | 16 |
| 2018 | 5 |
| 2019 | 3 |
| 2020 | 5 |
| 2021 | 2 |
| 2022 | 5 |
| 2023 | 3 |
| 2024 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 158 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Novartis Pharmaceuticals | 12 |
| Celgene | 11 |
| Children's Oncology Group | 8 |
| AstraZeneca | 7 |
| Biogen | 6 |
| University Health Network, Toronto | 5 |
| National Cancer Institute (NCI) | 4 |
| Therapeutic Advances in Childhood Leukemia Consortium | 4 |
| pharmaand GmbH | 4 |
| AbbVie | 3 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Recurrence | 158 |
| Leukemia | 21 |
| Multiple Myeloma | 20 |
| Neoplasms | 19 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 18 |
| Leukemia, Myeloid, Acute | 16 |
| Lymphoma | 16 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 13 |
| Multiple Sclerosis | 12 |
| Ovarian Neoplasms | 11 |
Trials
Showing 1 to 25 of 158. Each trial links to its page on Pharma Observatory.
58 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.